Conditions: Metastatic Melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which cannot be removed by surgery.

Detailed description:

Arms:
arm 1: IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles

Interventions: intervention 1: Ipilimumab intervention 2: GM-CSF
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: